Spruce (SPRB) news
Recent news
Spruce Biosciences: Ta-ert EAP and transform study expected to initiate in Q4 2026
Spruce Biosciences, Inc. (Nasdaq: SPRB) has confirmed that its planned Biologics License Application (BLA) for tralesinidase alfa enzyme replacement therapy (TA-ERT) remains on track for submission in the fourth quarter of 2026, following positive pre-BLA meetings with the FDA . The company has…
AInvest Wire · 5d agoSpruce: confirms BLA submission for TA-ERT on track for 4Q
Spruce Biosciences, Inc. (Nasdaq: SPRB) has confirmed that its Biologics License Application (BLA) submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) remains on track for the fourth quarter of 2026. The company recently concluded two Type B meetings with the U.S. Food and Drug…
AInvest Wire · 7d agoSpruce Biosciences: positive pre-BLA meetings with FDA
AInvest Wire · 7d agoSpruce Biosciences: FDA and Spruce aligned on content and format of planned BLA
AInvest Wire · 7d agoSpruce Biosciences pursuing accelerated approval pathway based on reduction of CSF HS-NRE
AInvest Wire · 7d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.